NVIVQ — InVivo Therapeutics Holdings Balance Sheet
0.000.00%
- $1.06m
- -$7.53m
- 12
- 57
- 19
- 19
Annual balance sheet for InVivo Therapeutics Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 16.7 | 6.6 | 19.5 | 19 | 16.4 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 17.1 | 6.78 | 19.7 | 19.1 | 17.6 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.1 | 1.28 | 1.01 | 1.36 | 1.07 |
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 18.4 | 9.32 | 21.9 | 21.8 | 18.8 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 2.21 | 2.66 | 1.97 | 2.61 | 2.47 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 2.27 | 3.74 | 2.72 | 3.65 | 3.08 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 16.1 | 5.58 | 19.2 | 18.1 | 15.7 |
| Total Liabilities & Shareholders' Equity | 18.4 | 9.32 | 21.9 | 21.8 | 18.8 |
| Total Common Shares Outstanding |